Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins

Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1

(2015) Fatima Ali-Rahmani et al.   CANCER RESEARCH

Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives

(2015) Silvia Ortolani et al.   Future Oncology

Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity

(2015) Matteo Pasetto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin

(2014) A. Antignani et al.   MOLECULAR CANCER THERAPEUTICS

Novel bacterial ADP-ribosylating toxins: structure and function

(2014) Nathan C. Simon et al.   NATURE REVIEWS MICROBIOLOGY

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells

(2013) Kevin Hollevoet et al.   JOURNAL OF IMMUNOTHERAPY

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P

(2013) Abid R. Mattoo et al.   PLoS One

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

(2012) Abid R. Mattoo et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

(2012) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

(2011) Brian Magnuson et al.   BIOCHEMICAL JOURNAL

The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

(2011) Taj D. King et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Clinical Experience to Date With Nilotinib in Gastrointestinal Stromal Tumors

(2011) Peter Reichardt et al.   SEMINARS IN ONCOLOGY

Newly Discovered and Characterized Antivirulence Compounds Inhibit Bacterial Mono-ADP-Ribosyltransferase Toxins

(2010) Zachari Turgeon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol

(2010) R. Traini et al.   MOLECULAR CANCER THERAPEUTICS

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

(2009) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus

(2009) Michael B. Atkins et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Mechanisms of the Cytotoxicity of ADP-Ribosylating Toxins

(2008) Qing Deng et al.   Annual Review of Microbiology